Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts

Informazioni relative al progetto

IMMUcan

ID dell’accordo di sovvenzione: 821558

DOI

10.3030/821558

Data della firma CE 23 Aprile 2019

Data di avvio 1 Marzo 2019

Data di completamento 30 Giugno 2026

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 37 187 251,00

Contributo UE

€ 17 830 000,00

Coordinato da

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
Belgium

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (3)

Independent boards (EAB and SAB) up and constituted

Report on the composition of these boards.

Policy for third party access and use of project results

On month 1, it will be an agreement on the key principles regarding 3rd party access allowing to discuss contract with non-EORTC groups. The full policy will be available by month 6.

Leaflet in lay language

Leaflet explaining the project in lay language.

Other (1)

First newsletter circulated

First newsletter

Pubblicazioni

Conference proceedings (10)

Abstract 176P Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study

Autori: A. Joaquin Garcia, J. Krawczyk, M. Rediti, K. Gogolewski, M. Możejko, S. Tissot, S. Rusakiewicz, L. Despland, M. Morfouace, R. Liechti, F. Marzetta, X. Wang, D. Vincent, J-C. Goeminne, J. Oliveira, H.S. Hong, M. Cesaroni, C. Sotiriou, E. Szczurek, L. Buisseret
Pubblicato in: Immuno-Oncology and Technology, 2023
Editore: Elsevier
DOI: 10.1016/j.iotech.2023.100635

Abstract 179P Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort

Autori: M. Rediti, A. Joaquin Garcia, S. Tissot, S. Rusakiewicz, L. Despland, M. Morfouace, R. Liechti, F. Marzetta, J. Oliveira, J-C. Goeminne, A. Capela Marques, L. Greillier, X. Wang, D. Vincent, H.S. Hong, M. Cesaroni, C. Sotiriou, L. Buisseret
Pubblicato in: Immuno-Oncology and Technology, 2023
Editore: Elsevier
DOI: 10.1016/j.iotech.2023.100638

Abstract 186P Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: An EORTC IMMUcan sub-project

Autori: A. Van Der Elst, D. Herrero Saboya, L. Michon, M. Morfouace, R. Liechti, D. Schulz, P. Devanand, R. Galot, A. Essabar, V. Pancaldi, J. Merlevede, H.S. Hong, L. Martignetti, C
Pubblicato in: Immuno-Oncology and Technology, 2023
Editore: Elsevier
DOI: 10.1016/j.iotech.2023.100645

Abstract 199P Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium

Autori: N. Eling, J. Dorier, S. Rusakiewicz, S. Tissot, P. Devanand, M. Daniel, S. Déglise, B. Palau Fernandez, J. Windhager, M. Możejko, K. Gogolewski, J. Krawczyk, A. Essabbar, V. Pancaldi, E. Szczurek, M. Morfouace, H.S. Hong, R. Liechti, B. Bodenmiller, D. Schulz
Pubblicato in: Immuno-Oncology and Technology, 2023
Editore: Elsevier
DOI: 10.1016/j.iotech.2023.100675

Abstract 195P IMMUcan: Toward a better understanding of the tumor microenvironment to inform precision oncology approaches

Autori: M. Morfouace, L. Buisseret, B. Besse, J-P. Machiels, C. Sotiriou, M-S. Robert, D. Schaer, S. Rusakiewicz, D. Schulz, B. Fournier, H.S. Hong, R. Liechti
Pubblicato in: Immuno-Oncology and Technology, 2023
Editore: Elsevier
DOI: 10.1016/j.iotech.2023.100654

Abstract 202P Discovery of immunological cellular neighborhoods from protein markers in spatial tumor data

Autori: M. Możejko, K. Gogolewski, D. Schulz, N. Eling, J. Krawczyk, A. Możwiłło, M. Daniel, E. Staub, M. Mourface, H.S. Hong, B. Bodenmiller, E. Szczurek
Pubblicato in: Immuno-Oncology and Technology, 2023
Editore: Elsevier
DOI: 10.1016/j.iotech.2023.100678

Abstract 2266P IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort

Autori: M. Morfouace, D. Schulz, N. Eling, F. Marzetta, C. Loizides, S. Rusakiewicz, R. Liechti, H.S. Hong, M-S. Robert, P. Bironzo, T. Cufer, K. Oselin, N. Cloarec, J. Oliveira, B. Bodenmiller, B. Besse,
Pubblicato in: Annals of Oncology, 2023
Editore: Elsevier
DOI: 10.1016/j.annonc.2023.09.1294

Abstract 4522: Pathologic complete response rate across triple negative breast cancer subtypes in the IMMUcan study

Autori: Andrea Joaquin Garcia; Mattia Rediti; Abdelkader Benyagoub; Stéphanie Tissot; Sylvie Rusakiewicz; Robin Liechti; Flavia Marzetta; Nicolas Penel; Julio Oliveira; Jean-Charles Goeminne; Pierre Fournel; Andreia Capela; Xiaoxiao Wang; Delphine Vincent; Françoise Rothe; Marie Morfouace; Henoch Hong; Donald Jackson; Christos Sotiriou; Laurence Buisseret
Pubblicato in: Immuno-Oncology and Technology, 2023
Editore: Elsevier
DOI: 10.1158/1538-7445.am2023-4522

Abstract 2274P: Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study

Autori: C. Esposito, A. Joaquin Garcia, M. Rediti, N. Penel, J. Oliveira, J-C. Goeminne, P. Fournel, A. Capela Marques, M. Morfouace, L. Buisseret, H.S. Hong, C. Maussion
Pubblicato in: Annals of Oncology, 2023
Editore: Elsevier
DOI: 10.1016/j.annonc.2023.09.1302

Abstract 1P Integrated data analysis within IMMUcan identifies prognostic features of early NSCLC

Autori: D. Schulz, M. Morfouace, N. Eling, M. Daniel, S. Déglise, B. Palau Fernandez, J. Windhager, S. Rusakiewicz, S. Tissot, T. Trefzer, J. Merlevede, F. Marzetta, R. Liechti, H.S. Hong, T. Cufer, P. Bironzo, A-M.C. Dingemans, B. Besse, B. Bodenmiller
Pubblicato in: Immuno-Oncology and Technology, 2023
Editore: Elsevier
DOI: 10.1016/j.iotech.2023.100473

Peer reviewed articles (3)

Yes, IMMUcan! Unraveling the human tumor microenvironment

Autori: Henoch Hong, Robin Liechti, Marie Morfouace
Pubblicato in: Immuno-Oncology Insights, Numero 2021; 2(5),, 2021, Pagina/e 301–309, ISSN 2059-7800
Editore: BioInsights Publishing Ltd
DOI: 10.18609/ioi.2021.038

CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy.

Autori: Franken A, Bila M, Mechels A, Kint S, Van Dessel J, Pomella V, Vanuytven S, Philips G, Bricard O, Xiong J, Boeckx B, Hatse S, Van Brussel T, Schepers R, Van Aerde C, Geurs S, Vandecaveye V, Hauben E, Vander Poorten V, Verbandt S, Vandereyken K, Qian J, Tejpar S, Voet T, Clement PM, Lambrechts D.
Pubblicato in: Immunity, 2024, ISSN 1097-4180
Editore: Elsevier
DOI: 10.1016/j.immuni.2024.02.007

Meta-analysis of human cancer single cell RNA-seq datasets using the IMMUcan database.

Autori: Jordi Camps; Floriane Noël; Robin Liechti; Lucile Massenet-Regad; Sidwell Rigade; Lou Götz; Caroline Hoffmann; Elise Amblard; Melissa Saichi; Mahmoud M. Ibrahim; Jack Pollard; Jasna Medvedovic; Helge G. Roider; Vassili Soumelis
Pubblicato in: Cancer Research, 2023, ISSN 1538-7445
Editore: AACR
DOI: 10.1158/0008-5472.can-22-0074